Cetuximab-Associated Elongation of the Eyelashes

    Philip R. Cohen, Susan Escudier, Razelle Kurzrock
    Studysummary This article reviews eyelash elongation as a side effect of EGFR inhibitors in cancer treatment, finding that the condition is typically not severe and may be managed by trimming.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 8

    1. Lymphocytic Infiltration of the Skin Jessner-Kanof After Treatment With a Hydroquinone-Containing Bleaching Cream Archives of dermatology · 2006
    2. Non-Rash Skin Toxicities Associated with Novel Targeted Therapies Clinical lung cancer · 2006
    3. The PRIDE Syndrome: Dermatological Side Effects of EGFR Inhibitors British Journal of Dermatology · 2006
    4. Nonscarring Inflammatory Alopecia Associated With the Epidermal Growth Factor Receptor Inhibitor Gefitinib Journal of the American Academy of Dermatology · 2006
    5. Trichomegaly of the Eyelashes Following Treatment with Cetuximab Annals of oncology · 2005
    6. Follicular and Epidermal Alterations in Patients Treated with ZD1839 (Iressa), an Inhibitor of the Epidermal Growth Factor Receptor British journal of dermatology/British journal of dermatology, Supplement · 2002
    7. Expression of a Dominant Negative Mutant of Epidermal Growth Factor Receptor in the Epidermis of Transgenic Mice Elicits Striking Alterations in Hair Follicle Development and Skin Structure. The EMBO Journal · 1995
    8. Immunolocalization of Epidermal Growth Factor Receptors in Normal Developing Human Skin Journal of Investigative Dermatology · 1990

    Related research 1

    1. Cetuximab-Associated Elongation of the Eyelashes American Journal of Clinical Dermatology · 2010